Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non-Current Debt (2021 - 2025)

Arcutis Biotherapeutics (ARQT) has 5 years of Non-Current Debt data on record, last reported at $108.0 million in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 0.71% year-over-year to $108.0 million; the TTM value through Dec 2025 reached $108.0 million, up 0.71%, while the annual FY2025 figure was $108.0 million, 0.71% up from the prior year.
  • Non-Current Debt reached $108.0 million in Q4 2025 per ARQT's latest filing, roughly flat from $107.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $203.8 million in Q2 2024 and bottomed at $72.4 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $144.9 million, with a median of $108.0 million recorded in 2025.
  • Peak YoY movement for Non-Current Debt: skyrocketed 173.35% in 2022, then tumbled 47.66% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $72.4 million in 2021, then surged by 173.35% to $197.8 million in 2022, then rose by 2.04% to $201.8 million in 2023, then tumbled by 46.88% to $107.2 million in 2024, then grew by 0.71% to $108.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $108.0 million in Q4 2025, $107.5 million in Q3 2025, and $107.0 million in Q2 2025.